Calmare Therapeutics Inc. (CTTC) financial statements (2021 and earlier)
Company profile
| Business Address |
1375 KINGS HIGHWAY EAST FAIRFIELD, CT 06824 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 0 | 0 | 0 | 0 | 0 | ||
| Cash and cash equivalents | 0 | 0 | 0 | 0 | 0 | ||
| Receivables | 0 | 0 | 0 | 0 | 0 | ||
| Inventory, net of allowances, customer advances and progress billings | 4 | 4 | |||||
| Inventory | 4 | 4 | |||||
| Prepaid expense | 0 | 0 | 0 | 0 | ✕ | ||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 0 | ||
| Other undisclosed current assets | 4 | 4 | 4 | ||||
| Total current assets: | 4 | 4 | 4 | 5 | 5 | ||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | ||
| TOTAL ASSETS: | 4 | 4 | 4 | 5 | 5 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 8 | 4 | 4 | 1 | 3 | ||
| Accounts payable | 2 | 2 | 1 | 1 | 2 | ||
| Accrued liabilities | 3 | 2 | 2 | 1 | 1 | ||
| Employee-related liabilities | 0 | 0 | |||||
| Interest and dividends payable | 2 | 1 | |||||
| Debt | 6 | 4 | 3 | 2 | 1 | ||
| Derivative instruments and hedges, liabilities | 0 | 0 | 0 | 0 | 0 | ||
| Deferred revenue and credits | 0 | ||||||
| Other undisclosed current liabilities | 4 | 6 | 5 | 7 | 5 | ||
| Total current liabilities: | 18 | 15 | 12 | 11 | 9 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 0 | 0 | 0 | ||||
| Long-term debt, excluding current maturities | 0 | 0 | 0 | ||||
| Total noncurrent liabilities: | 0 | 0 | 0 | ||||
| Total liabilities: | 18 | 15 | 12 | 11 | 9 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (14) | (10) | (8) | (6) | (4) | ||
| Preferred stock | 0 | ||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 49 | 49 | 48 | 46 | 45 | ||
| Accumulated deficit | (63) | (59) | (56) | (52) | (50) | ||
| Warrants and rights outstanding | 0 | ||||||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | (0) | 0 | ||
| Total stockholders' equity: | (14) | (10) | (8) | (6) | (4) | ||
| TOTAL LIABILITIES AND EQUITY: | 4 | 4 | 4 | 5 | 5 | ||
Income statement (P&L) ($ in millions)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 1 | 1 | 1 | 1 | 1 | |
| Cost of revenue (Cost of Goods and Services Sold) | (0) | (0) | (0) | (0) | (0) | |
| Other undisclosed gross profit | (0) | (0) | (0) | |||
| Gross profit: | 1 | 1 | 1 | 0 | 1 | |
| Operating expenses | (1) | (1) | (1) | (3) | (4) | |
| Other undisclosed operating loss | (2) | (2) | (2) | |||
| Operating loss: | (2) | (3) | (2) | (3) | (3) | |
| Nonoperating income (Investment Income, Nonoperating) | 0 | 0 | 0 | |||
| Interest and debt expense | (1) | (1) | (1) | (0) | (0) | |
| Loss from continuing operations before equity method investments, income taxes: | (4) | (4) | (3) | (3) | (3) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (0) | (0) | 0 | 0 | ||
| Net loss available to common stockholders, diluted: | (4) | (4) | (3) | (3) | (3) | |
Comprehensive Income ($ in millions)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (4) | (4) | (3) | (3) | (3) | |
| Comprehensive loss, net of tax, attributable to parent: | (4) | (4) | (3) | (3) | (3) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.